---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-060031"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T12:57:27.413821+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Agios Pharmaceuticals amends bylaws to update proxy rules and meeting procedures

## Summary
- Revised procedural mechanics for stockholder nominations under universal proxy rules.
- Requires additional background info and representations from proposing stockholders.
- Clarifies that failure to comply with Rule 14a-19 may result in disregarding nominations.
- Eliminates requirement to make stockholder list available during meeting.
- Adds emergency provisions limiting officer/director liability to willful misconduct.

## SEC filing metadata
- accession: 0001193125-23-060031
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/0001193125-23-060031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/d638020d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-060031
- JSON: https://secwatch.observer/filing/0001193125-23-060031.json
- Plain text: https://secwatch.observer/filing/0001193125-23-060031.txt

## Key facts
- Governance Changes
  AGIOS PHARMACEUTICALS, INC.: Amended and restated the bylaws to update procedural mechanics and disclosure requirements for stockholder nominations and proposals, among other changes (effective 2023-03-02).
  - Change: bylaw amendment
  - Effective: 2023-03-02
  source text: On March 2, 2023, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) approved an amendment and restatement of the Company’s Second Amended and Restated By-Laws (as so amended and restated, the “Third Amended and Restated By-Laws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/0001193125-23-060031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.